STEMBIOSYS INC has a total of 14 patent applications. It decreased the IP activity by 83.0%. Its first patent ever was published in 2015. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets biotechnology, pharmaceuticals and medical technology are CELLTRAN LTD, STEMCELL TECH CANADA INC and IHEART JAPAN CORP.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | Canada | 2 | |
#4 | Australia | 1 | |
#5 | China | 1 | |
#6 | EPO (European Patent Office) | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Medical technology | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Object sterilising | |
#5 | Medical preparations | |
#6 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Griffey Edward S | 14 |
#2 | Zamilpa Rogelio | 9 |
#3 | Block Travis | 5 |
#4 | Navarro Mary | 3 |
#5 | Herron Todd | 2 |
Publication | Filing date | Title |
---|---|---|
US2020270577A1 | Methods for the maturation of cardiomyocytes on amniotic fluid cell-derived ecm, cellular constructs, and uses for cardiotoxicity and proarrhythmic screening of drug compounds | |
WO2020072791A1 | Amniotic fluid cell-derived extracellular matrix and uses thereof | |
WO2017168343A1 | Bone marrow stromal cell derived extracellular matrix protein extract and uses thereof | |
US2017335286A1 | Methods for maintaining and expanding mesenchymal stem cells on extracellular matrix coated microcarriers |